Evidence map›Paper›PMID 36416014›Full record

ArticleThe Journal of infectious diseases2023

Deployment of a Reservoir-Targeted Vaccine Against Borrelia burgdorferi Reduces the Prevalence of Babesia microti Coinfection in Ixodes scapularis Ticks.

Edouard Vannier, Luciana M Richer, Duy M Dinh, Dustin Brisson, Richard S Ostfeld, Maria Gomes-Solecki

Open access · greenAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 5 citations in OpenAlex.

  1. Protective efficacy of mutant strains ofInfection and immunity · 2026
    Article
  2. Coinfection ecology and pathogen emergence in aApplied and environmental microbiology · 2026
    Article
  3. Article
  4. Review
  5. Coinfection Ecology and Pathogen Emergence in amedRxiv : the preprint server for health sciences · 2025
    Article
  6. Prevalence ofMicroorganisms · 2024
    Article
  7. Host-pathogen associations inferred from bloodmeal analyses ofApplied and environmental microbiology · 2024
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Edouard VannierDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA.
Luciana M RicherDepartment of Microbiology, Immunology and Biochemistry, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Duy M DinhDivision of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, Massachusetts, USA.
Dustin BrissonDepartment of Biology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Richard S OstfeldCary Institute of Ecosystem Studies, Millbrook, New York, USA.
Maria Gomes-SoleckiDepartment of Microbiology, Immunology and Biochemistry, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Tufts Medical Center · USUniversity of Tennessee Health Science Center · USCary Institute of Ecosystem Studies · USUniversity of Pennsylvania · US

Funding

Field trial and modeling of transmission blocking vaccine to prevent Lyme diseaseR01AI139267 · NIAID · UNIVERSITY OF IOWA · PI BROWN, GRANT D, GOMES-SOLECKI, MARIA · 2019 to 2023
$3.6M
Lab on a chip point of care assay for the rapid serodiagnosis of Lyme diseaseR44AI096551 · NIAID · IMMUNO TECHNOLOGIES, INC. · PI GOMES-SOLECKI, MARIA · 2014 to 2016
$3.0M
Intranasal Vaccine Against Lyme DiseaseR44AI167605 · NIAID · IMMUNO TECHNOLOGIES, INC. · PI GOMES-SOLECKI, MARIA · 2022 to 2024
$3.0M
WILDLIFE ORAL VACCINE AGAINST B. BURGDORFERIR44AI058364 · NIAID · BIOPEPTIDES, INC. · PI GOMES-SOLECKI, MARIA · 2004 to 2006
$1.0M
Lab on a chip point of care assay for the rapid serodiagnosis of Lyme diseaseR43AI096551 · NIAID · BIOPEPTIDES, INC. · PI GOMES-SOLECKI, MARIA · 2011 to 2012
$600k
BAIT VACCINE AGAINST LYME BORRELIOSISR43AI072810 · NIAID · BIOPEPTIDES, INC. · PI GOMES-SOLECKI, MARIA · 2007 to 2008
$600k
CDC HHS U01 CK000107NCEZID CDC HHS U01 CK000107NIAID NIH HHS R01 AI139267NIAID NIH HHS R43 AI096551NIAID NIH HHS R44 AI096551NIH HHS R43/R44 AI096551
6 · The paper itself

Abstract

In the Northeast and upper Midwest of the United States, Babesia microti and Borrelia burgdorferi use Ixodes scapularis ticks as vector and Peromyscus leucopus mice as major reservoir host. We previously established, in a 5-year field trial, that a reservoir-targeted outer surface protein A vaccine reduces the prevalence of B. burgdorferi-infected ticks. We accessed ticks and mouse blood samples collected during the trial, extracted total DNA, and amplified the B. microti 18S rRNA gene. Vaccine deployment reduced the prevalence of ticks coinfected with B. microti and that of mice infected with B. microti. Breaking the enzootic cycle of B. burgdorferi may reduce the incidence of babesiosis.

Indexed as

Babesia microtiBorrelia burgdorferiCoinfectionIxodesLyme DiseaseAnimalsBacterial VaccinesPeromyscusPrevalenceBacterial VaccinesBabesia microtibabesiosisBorrelia burgdorfericoinfectionLyme diseasePeromyscus leucopustickvaccine

Identifiers

PMID36416014
PMCPMC10175066
OpenAlexW4309724003

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.